D K Yu
Overview
Explore the profile of D K Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng T, Li H, Yuan P, Yu D, Ma F, Tan W, et al.
Zhonghua Zhong Liu Za Zhi
. 2017 Feb;
39(2):115-120.
PMID: 28219206
To explore the associations between genetic variations of glutathione synthetase gene (GSS) and response to platinum-based chemotherapy of small cell lung cancer(SCLC), and to analyze the influencing factors on survival....
2.
Yuan J, Han B, Chen R, Song L, Zhang Z, Zhang X, et al.
Zhonghua Yu Fang Yi Xue Za Zhi
. 2016 Aug;
50(8):747-52.
PMID: 27539531
No abstract available.
3.
Li H, Yuan P, Yu D, Ma F, Tan W, Feng T, et al.
Zhonghua Zhong Liu Za Zhi
. 2016 Aug;
38(7):504-9.
PMID: 27531263
Objective: To explore the associations between genetic variations of DNA repair gene RAD52 and response to platinum-based chemotherapy of small cell lung cancer (SCLC), and to analyze the influencing factors...
4.
Nong D, Li B, Yin B, Yu D, Zhou X, Zhu H
Zhongguo Ying Yong Sheng Li Xue Za Zhi
. 2011 Jan;
17(4):402-3.
PMID: 21207713
Aim: Because no ECG lead cable and lead selector is equipped, SYD-4228 Physiology Experiment System can not be used to record and observe ECG. This paper introduces an ECG lead...
5.
Yu D
J Clin Pharmacol
. 1999 Dec;
39(12):1203-11.
PMID: 10586385
P-glycoprotein (PGP) is well known because of its contribution to multiple-drug resistance during anticancer treatment. More recent work indicates that PGP mediates the transcellular transport of many drugs in addition...
6.
Yu D, Bhargava V, Weir S
J Clin Pharmacol
. 1997 Aug;
37(8):673-8.
PMID: 9378839
Pharmacokinetic variability is an important component of the total variability in drug response, but Phase II dose-response trials frequently are designed without considering this important factor. Mixed-effects model simulation was...
7.
Tammara V, Mahmood I, Yu D, Hileman G
Ther Drug Monit
. 1997 Feb;
19(1):79-82.
PMID: 9029752
A limited sampling model (LSM) was developed to estimate the area under the curve (AUC) and maximum plasma concentration (Cmax) for a 1-g oral dose of vigabatrin. The model was...
8.
McNamara R, Yu D, Kelly J
Am J Emerg Med
. 1997 Jan;
15(1):40-2.
PMID: 9002567
Violence within the emergency department (ED) is an area of concern for both the staff and public. Emergency physicians and nurses express a great deal of concern for their personal...
9.
Huang F, Hermann E, Wang J, Cheng X, Tsai W, Wen J, et al.
Infect Immun
. 1996 Jan;
64(1):120-7.
PMID: 8557329
HLA-B27 molecules expressed on the T2 mutant cell line do not have peptides. Such empty HLA-B27 molecules were not recognized by an HLA-B27-restricted cytotoxic T-lymphocyte (CTL) clone (auto-1) derived from...
10.
Yu D, Nordbrock E, Hutcheson S, Lewis E, Sullivan W, Bhargava V, et al.
J Pharmacokinet Biopharm
. 1995 Feb;
23(1):25-39.
PMID: 8576842
Teicoplanin is a new glycopeptide antibiotic, active against aerobic and anaerobic gram-positive bacteria. The drug is intended for the treatment of systemic infections including endocarditis. In two U.S. clinical safety...